ATLANTA, GA – – (Newsfile Corp. – August 18, 2021) – – Holzer & Holzer, LLC is investigating whether Sesen Bio, Inc. (“Sesen” or the “Company”) (NASDAQ: SESN) complied with federal securities laws. On August 13, 2021, SESN received a Complete Response Letter from U.S. Food and Drug Administration (“FDA”) and announced that the FDA had declined to approve the Biologics License Application for Vicineum. On this news, the price of the Company’s stock plummeted. If you purchased Sesen stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.